RVL Pharmaceuticals Reports Double-Digit Revenue Growth in Q3 2026, Advancing the Mission to Build the Leading Ocular Vitality Platform

BRIDGEWATER, N.J., Oct. 30, 2026 /PRNewswire/ -- RVL Pharmaceuticals Inc. and its affiliates (together, "RVL") announced strong third-quarter performance, with continued double-digit year-over-year revenue growth driven by increasing consumer demand, advancement of a new celebrity partnership, and an expansion of the RVL product line.

Upneeq^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the prescription eye drop for low-lying eyelids (acquired blepharoptosis), remains the category-defining asset at the center of RVL's fast growing, vertically integrated omnichannel platform.

RVL significantly expanded through a series of strategic growth initiatives designed to accelerate consumer awareness, create cultural relevance, and broaden the brand's role within ocular aesthetics. The company launched its first national consumer celebrity campaign in Q2. The breakthrough campaign, which continued to accelerate in Q3, introduced Upneeq to broader audiences and reinforced the brand's position at the intersection of clinical innovation and beauty, generating unprecedented awareness and elevating the brand's presence within the cultural conversation. The team also hosted a celebrity discussion with Dr. Elizabeth Hale, renowned NYC dermatologist, and Fat Mascara host, Jessica Matlin, with a packed room of top-tier media for a personal discussion about the beauty of connection. That same day, the team took to the streets for New York Fashion Week for consumers to discover and engage with the brand in real life. The event, spanning eyecare professionals to influencers, generated great buzz throughout the city.

RVL grew Upneeq Reveal™ Under Eye Complex, the company's first consumer product extension into skincare, expanding beyond prescription treatment into adjacent eye beauty occasions. Together, these initiatives expand RVL's addressable market, create additional consumer engagement opportunities, and establish additional pathways for lifetime value growth across prescription and consumer channels.

"Our third quarter marked an important step in our evolution from a prescription brand to establishing a broader presence in ocular aesthetics," said Lori Deo, Chief Executive Officer of RVL Pharmaceuticals. "The continued launch of our national celebrity campaign demonstrated how we're creating new ways to engage consumers, expand our addressable market, and drive sustainable long-term growth." The impact of these investments was evident on both consumer engagement and market visibility during the quarter.

"The market response to our celebrity campaign has been incredibly strong, meaningfully expanding engagement and generating broad earned media coverage, sparking conversations and education about low-lying eyelids for millions of potential new customers and introducing Upneeq as a treatment option for appropriate patients," said Amy Shah, Chief Growth Officer of RVL Pharmaceuticals. "The positive reaction reinforces both the relevance of our message and the size of the opportunity ahead. We're building a connected consumer journey that supports both acquisition and long-term engagement." Upneeq^® represents a category-defining asset at the intersection of aesthetics and eye care, with an estimated $2.5 billion total addressable market and significant headroom for continued penetration. Building on the momentum from the third quarter, RVL plans to continue investing in consumer awareness, innovation, and commercial capabilities that expand access to Upneeq, strengthen engagement across the customer journey, and reinforce the company's leadership position in ocular aesthetics.

About Upneeq^®

Upneeq^® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.

Warnings and Precautions: Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.

UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.

Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren's syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.

UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.

Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

Adverse Reactions

In clinical trials, the most common adverse reactions with UPNEEQ (occurring in 1–5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About Reveal Under Eye Complex

Upneeq Reveal™ Under Eye Complex is an expertly formulated under-eye treatment that brightens, firms, and smooths skin. Our specialized complex helps reduce the look of dark circles, fine lines, and wrinkles while nourishing the skin around the delicate eye area, for a more radiant, hydrated look.

Upneeq Reveal™ Under Eye Complex is a non-prescription cosmetic product. It does not include oxymetazoline.

About RVL Pharmaceuticals

RVL Pharmaceuticals operates a digitally enabled, vertically integrated commercial platform that combines consumer demand generation, healthcare provider engagement, telemedicine, pharmacy fulfillment, and data-driven insights to create seamless experiences for both patients and healthcare professionals.

Its lead product, Upneeq^®, a once-daily prescription eyedrop, provides a non-surgical eyelift for adults with acquired ptosis. Upneeq^® activates a muscle in the eyelids, lifting the lid for a more open and awake appearance. One drop daily to each affected eye works in minutes and can last up to eight hours.

The company recently expanded the Upneeq platform with the introduction of Upneeq Reveal™ Under Eye Complex, reinforcing RVL's commitment to innovation across eye aesthetics and ocular wellness.

For more information, please visit www.rvlpharma.com.

SOURCE RVL Pharmaceuticals, Inc